



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Kjell Bäckström et al.                      Art Unit : 1616  
Serial No. : 08/601,005                                      Examiner : F. Choi  
Filed : March 1, 1996  
Title : AEROSOL DRUG FORMULATIONS

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**TERMINAL DISCLAIMER UNDER 37 CFR §§3.73(b) AND 1.321(b)**

Pursuant to 37 CFR §3.73(b), AstraZeneca AB, a corporation, certifies that it is the assignee of the entire right, title, and interest in the above application (the '005 application) by virtue of an assignment from the inventors to Astra Aktiebolag. The assignment was recorded in the Patent and Trademark Office at Reel 9383, Frame 0433 on May 5, 1998. The name of Astra Aktiebolag has been changed to AstraZeneca AB, which name change was recorded in the Patent and Trademark Office at Reel 013568, Frame 0119 on December 12, 2002.

AstraZeneca AB also certifies that it is the assignee of the entire right, title, and interest in U.S. Patent No. 6,524,557 (the '557 patent), by virtue of an assignment from the inventors of the '557 patent to Astra Aktiebolag recorded in the Patent and Trademark Office at Reel 9188, Frame 0030, on April 5, 1996. The name change to AstraZeneca AB was recorded for the '557 patent at Reel 013567, Frame 0491, on December 11, 2002.

The undersigned has reviewed all the documents in the chain of title of the above-identified application, and, to the best of undersigned's knowledge and belief, title is in AstraZeneca AB.

The undersigned is empowered to act on behalf of the assignee.

Pursuant to 37 CFR §1.321(b), and to obviate a double patenting rejection, the assignee identified above hereby waives and disclaims the terminal portion of the term of the entire patent to be granted upon the '005 application subsequent to the expiration date of the '557 patent, provided that any patent granted on the '005 application shall be enforceable only for and during such period that it is commonly owned with the '557 patent.

03/08/2005 SSITHIB1 00000070 08601005

03 FC:1814

130.00 OP

CERTIFICATE OF MAILING BY EXPRESS MAIL

Express Mail Label No. EV 411926447 US

March 2, 2005  
Date of Deposit

Applicant : Kjell Bäckström et al.  
Serial No. : 08/601,005  
Filed : March 1, 1996  
Page : 2 of 2

Attorney's Docket No.: 06275-034001 / D 1371-1 US

The assignee identified above does not disclaim any terminal part of any patent granted on the '005 application prior to the expiration date of the full statutory term of the '557 patent in the event that the '557 patent later: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR §1.321(a), has all claims cancelled by a reexamination certificate, or is otherwise terminated prior to expiration of its statutory term, except for the separation of legal title as stated above. Assignee herein does not disclaim or otherwise affect any part of the '557 patent.


This disclaimer runs with any patent granted on the above application and is binding upon the grantee, its successors or assigns.

Enclosed is a check for \$130 for the required fee pursuant to 37 CFR §1.20(d). Please charge any additional fees, or make any credits, to Deposit Account No. 06-1050, referencing Attorney Docket No. 06275-034001.

Respectfully submitted,

Date

Feb. 23, 2005



Janis K. Fraser, Ph.D., J.D.  
Reg. No. 34,819

Fish & Richardson P.C.  
225 Franklin Street  
Boston, MA 02110-2804  
Telephone: (617) 542-5070  
Facsimile: (617) 542-8906